Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells

por Gupta, Sumati, Doyle, Kelly, Mosbruger, Timothy L., Butterfield, Andrew, Weston, Alexis, Ast, Allison, Kaadige, Mohan, Verma, Anupam, Sharma, Sunil
Publicado 2018

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

por Soldi, Raffaella, Ghosh Halder, Tithi, Weston, Alexis, Thode, Trason, Drenner, Kevin, Lewis, Rhonda, Kaadige, Mohan R., Srivastava, Shreyesi, Daniel Ampanattu, Sherin, Rodriguez del Villar, Ryan, Lang, Jessica, Vankayalapati, Hariprasad, Weissman, Bernard, Trent, Jeffrey M., Hendricks, William P. D., Sharma, Sunil
Publicado 2020